The supply of Radiopharmaceuticals for use in Petct including Fludeoxyglucose F18 and PSMA.

This is a VEAT notice to indicate that the Mater Misericordiae University Hospital (MMUH) intends to utilize EU public procurement directive Art 32.2(b) (iii) negotiated procedure without prior publication in the following case. (B) Where works, supplies or services can be supplied only by a particular economic operator for any of the following reasons: (iii) competition is absent for technical reasons. This notice is to indicate that the Mater Misericordiae University Hospital (MMUH) intends to contract with Curium Pharma Ireland Limited for a 4 year period for the continued provision of the Fludeoxyglucose F18 (FDG) and prostate-specific membrane antigen (PSMA) radiotracers which are employed within the PET/CT facility to facilitate the accurate diagnosis of malignant diseases. These products are essential for the operation of the hospital’s PET/CT facility and are required to enable accurate diagnosis and monitoring of cancers. The justification for this decision is that Curium is the sole licensed provider of these radiopharmaceuticals within the jurisdiction. No other economic operator holds the necessary authorisations or regulatory approvals to manufacture, distribute, and supply these products for clinical use in Ireland. MMUH is aware that an alternative provider may enter the market in 13-18 months. The hospital is entering into a 4 year contract on the basis of : Economic Efficiency: A four-year contract offers significantly lower total cost compared to shorter-term alternatives, even when factoring in the potential entry of a new supplier in 13-18 months. Market Uncertainty: While a new supplier is expected to enter the market in approximately two years, there is no guarantee regarding their operational readiness, regulatory approvals, or ability to meet the hospital’s supply requirements at that time. Continuity of Supply: The selected provider has demonstrated proven capability and reliability in delivering the required product. A four-year term ensures uninterrupted service and mitigates risks associated with supplier transition or market instability. Conclusion: The contracting authority considers that no reasonable alternative or substitute exists at present and that competition is absent for technical and economic reasons. The direct award is necessary to ensure continuity of service and value for money.